 |
New Reagents
Join our email list
Sign up to receive our latest product releases.
Recently Published Articles
Dong M et al.
ERdj4 and ERdj5 are required for endoplasmic reticulum-associated protein degradation of misfolded surfactant protein C. Mol. Biol. Cell 2008;19:2620-2630.
Stahlman MT et al.
Expression of ABCA3 in developing lung and other tissues. J Histochem Cytochem 2007;55:71-83.
|
|
 | Pulmonary Specialist Jeffrey A. Whitsett, MD |
|
|
|
Jeffrey A. Whitsett, MD, is the Director of the Section of Neonatology, Perinatal and Pulmonary Biology at Cincinnati Children's Hospital Medical Center.
Dr. Whitsett is internationally known for his research in pulmonary medicine, as well as for his clinical expertise in neonatology. Dr. Whitsett has made a series of groundbreaking contributions in pulmonary medicine. His major pioneering work has been on surfactant proteins A, B, C, and D, cloning their genes, and clarifying their roles in lung development. During the course of Dr. Whitsett’s research, he has developed a large repertoire of high quality antibody reagents that have been supplied to numerous research and diagnostic laboratories throughout the world. Over 25 of Dr. Whitsett’s antibodies are currently marketed through license agreements with different commercial partners. For example, Dr. Whitsett’s monoclonal antibody against TTF-1 is in wide use in pathology laboratories to help diagnose lung adenocarcinomas. Dr. Whitsett continues to develop and test new reagents required for his research that are in demand in the broader scientific community.
Jeffrey A. Whitsett at Cincinnati Children's Hospital Medical Center |
 |
|
|
